Drug intelligence / Profile preview

camrelizumab + anti-angiogenic TKIs + irinotecan

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

Camrelizumab + anti-angiogenic TKIs + irinotecan is a combination therapeutic regimen being evaluated for the treatment of metastatic colorectal mucinous adenocarcinoma (MAC). The regimen consists of camrelizumab (a PD-1 inhibitor), a choice of anti-angiogenic tyrosine kinase inhibitors (TKIs) including fruquintinib, regorafenib, or apatinib, and the chemotherapy agent irinotecan. Camrelizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor to restore anti-tumor T-cell activity. The TKIs target vascular endothelial growth factor receptors (VEGFR) to inhibit tumor angiogenesis, while irinotecan acts as a topoisomerase I inhibitor to disrupt DNA replication. This combination is primarily being studied in a Phase II clinical trial (NCT04446091) sponsored by Zhejiang Cancer Hospital.

Brand names: AiRuiKaElunateStivargaAiTan
Other names: carilizumab + anti-angiogenic TKIs + irinotecancamrelizumab + anti-angiogenic drugs + chemotherapy

Targets

BCL2L1 (B-cell lymphoma-extra large protein)TOP1 (DNA Topoisomerase I)MDM2 (Mouse double minute 2 homolog)PDCD1 (Programmed cell death protein 1 receptor)VEGFR (VEGFR family)

Beyond the preview

Go deeper on camrelizumab + anti-angiogenic TKIs + irinotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on camrelizumab + anti-angiogenic TKIs + irinotecan.

Explore the full profile